Melanotan-2 calculators

This hub gathers the four Melanotan-2 calculators in one place — reconstitution, dose, mg ↔ units, and vial duration — pre-filled with a 10 mg / 2 mL example so the math is concrete the moment the page loads. Melanotan-2 sits in the Melanocortin category, and the numbers each tool surfaces are tuned to how people actually log this peptide: a daily shot at the 0.5 mg example dose. A melanocortin agonist. Calculator example uses a daily 0.5 mg illustrative dose.

At the example concentration of 5 mg/mL, a 0.5 mg Melanotan-2 dose draws roughly 10 units on a U-100 insulin syringe — the Dose calculator on the hub shows that working in real time, and the mg ↔ units converter flips it back the other way for people who think in milligrams. The Reconstitution calculator answers the day-one question (how much bacteriostatic water to add and what concentration that gives), and the Vial Duration calculator answers the planning question (how many weeks one vial covers).

For this 10 mg Melanotan-2 vial, the example numbers imply about 20 doses per vial and roughly 2.9 weeks of coverage at 7 doses per week — that's the math the Vial Duration tool exposes, and it's the number most people use to decide when to reorder. Every calculator on the hub uses these same five inputs (vial mg, diluent mL, dose, doses-per-week, syringe type), so changing your real numbers in one tool gives consistent answers across the others.

Loading-phase protocols are typically daily; maintenance-phase protocols are less frequent. Recording the transition from loading to maintenance explicitly in the log is what makes the phase change auditable later.

A common protocol structure documented in personal logs for Melanotan-2 involves two distinct phases: a 'loading' phase and a 'maintenance' phase. The initial loading phase typically consists of small, frequently administered doses. Users may plan to schedule these administrations daily or every other day over a period of 7 to 21 days. The objective from a data-logging perspective is not simply to document the passage of time, but to track the cumulative dose required to reach a specific, observable endpoint. Meticulously recording each administration during this period allows for a granular analysis of the dose-response relationship unique to the individual.

Upon reaching the desired response level, users typically transition to a maintenance phase. This involves adjusting the schedule to a less frequent cadence, such as once or twice per week, to sustain the observed state. The dose amount may also be adjusted during this phase. Logging the specific date of this transition is one of the most critical data entry points for any long-term tracking plan. This marker allows calculation tools to properly attribute dosage and observations to either the initial accumulation period or the subsequent sustainment period, providing a clear and auditable record for personal review.